The global In Vitro Diagnostics Market is projected to be valued at USD 108.3 billion in 2024 and reach USD 150.13 billion by 2030, growing at a CAGR of 5.62% according to a new report by The Research ...

Qiagen has a relatively well-diversified portfolio across four segments. Find out my recommendation on QGEN stock here.

Cancer care has changed dramatically over the last decade. As opposed to a "one-size-fits-all" approach, treatment today is ...

Preconfigured applications: DRAGEN v4.4 will offer "push-button" analysis for oncology workflows, including the first and ...

Emergen Research Logo Driven by Advances in Gene Sequencing and Growing Need for Precision MedicineVANCOUVER, BRITISH COLUMBIA, CA ...

This special edition of Data Spotlight explores how research data, such as supply chain insights and geographic segment ...

QIAGEN N.V. QGEN recently signed a definitive agreement to acquire Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests.

Nucleus founder Kian Sadeghi’s story is anything but conventional. He has bold ambitions for 23andMe and the genetic testing industry.

The Centre for Advanced Spatial Analysis (CASA) is an interdisciplinary institute focusing on the science of cities within The Bartlett Faculty of the Built Environment at UCL. We bring together some ...

Analysts have recently evaluated NeoGenomics and provided 12-month price targets. The average target is $12.94, accompanied ...